Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Immunol Res ; 2019: 2745286, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31781674

RESUMEN

Viper snake Crotalus durissus ruruima (Cdr) is a subspecies found in northern area of Brazil. Among the snakes of Crotalus genus subspecies, the venom of Cdr presents highest level of crotoxin, which is the major component of Crotalus snake venoms, formed by two subunits (crotapotin and a phospholipase A2 named CBr) and presents potent neurotoxic activity. Curiously, the venom of C. d. ruruima (CdrV) is better neutralized by antibothropic than by anticrotalic serum, strongly suggesting that this venom has similarities with venom of Bothrops genus snakes with regard to the ability to induce inflammation. Macrophages are cells with a central role in inflammatory and immunological responses. Upon inflammatory stimuli, these cells exhibit increased numbers of lipid droplets, which are key organelles in the synthesis and release of inflammatory mediators. However, the effects of CdrV and CBr in macrophage functions are unknown. We herein investigated the ability of CdrV and CBr to activate macrophages with focus on the formation of lipid droplets (LDs), synthesis of lipid mediators, and mechanisms involved in these effects. The involvement of LDs in PGE2 biosynthesis was also assessed. Stimulation of murine macrophages with CdrV and CBr induced an increased number of LDs and release of prostanoids (PGE2, PGD2, and TXB2). Neither CdrV nor CBr induced the expression of COX-1 and COX-2 by macrophages. LDs induced by both CdrV and CBr are associated to PLIN2 recruitment and expression and were shown to be dependent on COX-1, but not COX-2 activity. Moreover, PGE2 colocalized to CdrV- and CBr-induced LDs, revealing the role of these organelles as sites for the synthesis of prostanoids. These results evidence, for the first time, the ability of a whole snake venom to induce formation of LDs and the potential role of these organelles for the production of inflammatory mediators during envenomation by Crotalus snakes.


Asunto(s)
Crotalus , Mediadores de Inflamación/metabolismo , Gotas Lipídicas/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Fosfolipasas A2/aislamiento & purificación , Fosfolipasas A2/farmacología , Venenos de Serpiente/aislamiento & purificación , Venenos de Serpiente/toxicidad , Animales , Células Cultivadas , Crotalus/metabolismo , Dinoprostona/metabolismo , Relación Dosis-Respuesta a Droga , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/metabolismo , Masculino , Ratones , Perilipina-2/genética , Perilipina-2/metabolismo , Prostaglandina-Endoperóxido Sintasas/metabolismo
2.
Mediators Inflamm ; 2018: 2547918, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30013451

RESUMEN

MT-III, a snake venom GIIA sPLA2, which shares structural and functional features with mammalian GIIA sPLA2s, activates macrophage defense functions including lipid droplet (LDs) formation, organelle involved in both lipid metabolism and inflammatory processes. Macrophages (MΦs) loaded with LDs, termed foam cells, characterize early blood vessel fatty-streak lesions during atherosclerosis. However, the factors involved in foam cell formation induced by a GIIA sPLA2 are still unknown. Here, we investigated the participation of lipid homeostasis-related factors in LD formation induced by MT-III in macrophages. We found that MT-III activated PPAR-γ and PPAR-ß/δ and increased the protein levels of both transcription factors and CD36 in macrophages. Pharmacological interventions evidenced that PPAR-γ, PPAR-ß/δ, and CD36 as well as the endoplasmic reticulum enzymes ACAT and DGAT are essential for LD formation. Moreover, PPAR-ß/δ, but not PPAR-γ, is involved in MT-III-induced PLIN2 protein expression, and both PPAR-ß/δ and PPAR-γ upregulated CD36 protein expression, which contributes to MT-III-induced COX-2 expression. Furthermore, production of 15-d-PGJ2, an activator of PPARs, induced by MT-III, was dependent on COX-1 being LDs an important platform for generation of this mediator.


Asunto(s)
Células Espumosas/efectos de los fármacos , Homeostasis , Lípidos/química , Fosfolipasas A2/farmacología , Venenos de Serpiente/enzimología , Animales , Antígenos CD36/metabolismo , Retículo Endoplásmico/metabolismo , Metabolismo de los Lípidos , Masculino , Ratones , PPAR alfa/metabolismo , PPAR delta/metabolismo , PPAR gamma/metabolismo , PPAR-beta/metabolismo , Prostaglandina D2/análogos & derivados , Prostaglandina D2/metabolismo , Transducción de Señal , Factores de Transcripción/metabolismo , Regulación hacia Arriba
3.
Sci Rep ; 7(1): 4098, 2017 06 22.
Artículo en Inglés | MEDLINE | ID: mdl-28642580

RESUMEN

Crotoxin B (CB) is a catalytically active group IIA sPLA2 from Crotalus durissus terrificus snake venom. In contrast to most GIIA sPLA2s, CB exhibits anti-inflammatory effects, including the ability to inhibit leukocyte functions. Lipid droplets (LDs) are lipid-rich organelles associated with inflammation and recognized as a site for the synthesis of inflammatory lipid mediators. Here, the ability of CB to induce formation of LDs and the mechanisms involved in this effect were investigated in isolated macrophages. The profile of CB-induced 15-d-PGJ2 (15-Deoxy-Delta-12,14-prostaglandin J2) production and involvement of LDs in 15-d-PGJ2 biosynthesis were also investigated. Stimulation of murine macrophages with CB induced increased number of LDs and release of 15-d-PGJ2. LDs induced by CB were associated to PLIN2 recruitment and expression and required activation of PKC, PI3K, MEK1/2, JNK, iPLA2 and PLD. Both 15-d-PGJ2 and COX-1 were found in CB-induced LDs indicating that LDs contribute to the inhibitory effects of CB by acting as platform for synthesis of 15-d-PGJ2, a pro-resolving lipid mediator. Together, our data indicate that an immunomodulatory GIIA sPLA2 can directly induce LD formation and production of a pro-resolving mediator in an inflammatory cell and afford new insights into the roles of LDs in resolution of inflammatory processes.


Asunto(s)
Fosfolipasas A2 Grupo II/metabolismo , Fosfolipasas A2 Grupo II/farmacología , Gotas Lipídicas/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Prostaglandina D2/análogos & derivados , Venenos de Serpiente/enzimología , Animales , Células Cultivadas , Ciclooxigenasa 1/metabolismo , Citoplasma/metabolismo , Inmunohistoquímica , Proteínas de la Membrana/metabolismo , Ratones , Perilipina-2/metabolismo , Prostaglandina D2/metabolismo , Transducción de Señal/efectos de los fármacos
4.
PLoS One ; 9(4): e93741, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24718259

RESUMEN

The snake venom MT-III is a group IIA secreted phospholipase A2 (sPLA2) enzyme with functional and structural similarities with mammalian pro-inflammatory sPLA2s of the same group. Previously, we demonstrated that MT-III directly activates the innate inflammatory response of macrophages, including release of inflammatory mediators and formation of lipid droplets (LDs). However, the mechanisms coordinating these processes remain unclear. In the present study, by using TLR2-/- or MyD88-/- or C57BL/6 (WT) male mice, we report that TLR2 and MyD88 signaling have a critical role in MT-III-induced inflammatory response in macrophages. MT-III caused a marked release of PGE2, PGD2, PGJ2, IL-1ß and IL-10 and increased the number of LDs in WT macrophages. In MT-III-stimulated TLR2-/- macrophages, formation of LDs and release of eicosanoids and cytokines were abrogated. In MyD88-/- macrophages, MT-III-induced release of PGE2, IL-1ß and IL-10 was abrogated, but release of PGD2 and PGJ2 was maintained. In addition, COX-2 protein expression seen in MT-III-stimulated WT macrophages was abolished in both TLR2-/- and MyD88-/- cells, while perilipin 2 expression was abolished only in MyD88-/- cells. We further demonstrated a reduction of saturated, monounsaturated and polyunsaturated fatty acids and a release of the TLR2 agonists palmitic and oleic acid from MT-III-stimulated WT macrophages compared with WT control cells, thus suggesting these fatty acids as major messengers for MT-III-induced engagement of TLR2/MyD88 signaling. Collectively, our findings identify for the first time a TLR2 and MyD88-dependent mechanism that underlies group IIA sPLA2-induced inflammatory response in macrophages.


Asunto(s)
Fosfolipasas A2 Grupo II/farmacología , Macrófagos/metabolismo , Factor 88 de Diferenciación Mieloide/metabolismo , Venenos de Serpiente/enzimología , Receptor Toll-Like 2/metabolismo , Animales , Ciclooxigenasa 2/metabolismo , Ácidos Grasos/metabolismo , Interleucina-10/metabolismo , Interleucina-1beta/metabolismo , Gotas Lipídicas/efectos de los fármacos , Gotas Lipídicas/metabolismo , Macrófagos/efectos de los fármacos , Masculino , Proteínas de la Membrana/metabolismo , Ratones Endogámicos C57BL , Factor 88 de Diferenciación Mieloide/deficiencia , Perilipina-2 , Prostaglandinas/biosíntesis , Transducción de Señal/efectos de los fármacos , Fracciones Subcelulares/efectos de los fármacos , Fracciones Subcelulares/metabolismo , Receptor Toll-Like 2/deficiencia , Regulación hacia Arriba/efectos de los fármacos
5.
Int J Mol Sci ; 13(11): 15305-20, 2012 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-23203127

RESUMEN

Long-term nonsteroidal anti-inflammatory drugs (NSAIDs) therapy has been associated with several adverse effects such as gastric ulceration and cardiovascular events. Among the molecular modifications strategies, the prodrug approach is a useful tool to discover new safe NSAIDs. The 1-(2,6-dichlorophenyl)indolin-2-one is a diclofenac prodrug which demonstrated relevant anti-inflammatory properties without gastro ulceration effect. In addition, the prodrug decreases PGE(2) levels, COX-2 expression and cellular influx into peritoneal cavity induced by carrageenan treatment. Preliminary pharmacokinetic studies have shown in vivo bioconversion of prodrug to diclofenac. This prodrug is a new nonulcerogenic NSAID useful to treat inflammatory events by long-term therapy.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Diclofenaco/farmacología , Profármacos , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Carragenina/efectos adversos , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Diclofenaco/administración & dosificación , Diclofenaco/efectos adversos , Diclofenaco/análogos & derivados , Diclofenaco/química , Diclofenaco/farmacocinética , Dinoprostona/biosíntesis , Modelos Animales de Enfermedad , Edema/inducido químicamente , Edema/tratamiento farmacológico , Leucocitos/metabolismo , Masculino , Ratones , Estructura Molecular , Cavidad Peritoneal/patología , Ratas , Úlcera Gástrica/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...